-
The two companies will join forces to enter the tens of billions of cardiovascular disease treatment market
Time of Update: 2021-12-26
(Skyline Therapeutics, hereinafter referred to as "Nine-Day Bio", the original Geneception), and BioMarin announced that they have reached a multi-year global strategic cooperation to jointly research and develop adeno-associated virus (AAV) ) New gene therapy for the treatment of hereditary cardiovascular diseases .
-
Over 200 listed companies have been investigated by fund companies!
Time of Update: 2021-12-26
In addition, the companies that Harvest Fund has investigated since December are also mainly in the pharmaceutical and biological, mechanical equipment, and electronics industries .
According to the main content of investor relations activities, the institutions mainly focus on the company’s three major medical hospitals.
-
At the end of the year, the wave of mergers and acquisitions of pharmaceutical companies continued!
Time of Update: 2021-12-26
In recent years, due to the difficulty, time-consuming, labor-intensive, and costly research and development of new drugs, many pharmaceutical companies have vigorously made some new investment arrangements in order to increase corporate operating profits, enrich drug pipelines, and reduce R&D expenditures .
-
Better Pharmaceuticals is working hard!
Time of Update: 2021-12-26
At present, more than 30 domestic companies have submitted applications for the listing of ticagrelor tablets under the new registration classification, of which 20 have been approved for production and deemed to have been reviewed.
-
The modernization of Chinese medicine is accelerating, and the Chinese medicine industry also urgently needs to speed up "machine substitution"
Time of Update: 2021-12-26
According to reports, in December 2019, the company's "Modernization of Traditional Chinese Medicine Manufacturing-Research and Application of Key Technologies for the Industrialization of Solid Preparations" also won the award .
-
Hansen Pharmaceutical's introduction of "first-in-class" antifungal drug was approved for Phase 3 clinical trials in China
Time of Update: 2021-12-26
ArticleMedicine GuanlanAccording to the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (CDE) and public information, Scinexis's oral antibacterial drug ibrexafungerp tablet has obtained the implied license of the clinical trial, and will start the treatment of vulvovaginal candidiasis (VVC) in China.
-
The export of raw materials is strong, and the pharmaceutical equipment industry is accelerating the layout
Time of Update: 2021-12-26
The industry believes that with the continuous growth of domestic enterprise API exports, API pharmaceutical equipment companies will also usher in more new opportunities .
-
The first domestically produced PD-(L)1 monoclonal antibody head-to-head Phase 3 clinical trial!
Time of Update: 2021-12-26
Today, Chia Tai Tianqing Pharmaceutical Group announced the launch of an "evaluation of TQB2450 injection combined with platinum-containing chemotherapy followed by sequential TQB2450 injection combined with anlotinib hydrochloride capsules versus tislelizumab injection combined with platinum-containing chemotherapy as the first-line treatment A randomized, open-label, parallel-controlled, multi-center phase III clinical trial on the effectiveness and safety of advanced non-squamous non-small cell lung cancer" .
-
Amgen/AstraZeneca first in class TSLP inhibitor approved by FDA for marketing
Time of Update: 2021-12-26
Thymus stromal lymphopoietin (TSLP) is a key epithelial cytokine, located at the top of multiple inflammatory cascades, and triggers an excessive immune response to airway inflammation related to severe asthma such as allergies and eosinophils .
-
Hausen Pharmaceuticals' new adaptation of Ametinib is approved for the first-line treatment of non-small cell lung cancer
Time of Update: 2021-12-26
According to the public information of priority review, the approved indications for this drug are: adults with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 (L858R) substitution mutation First-line treatment for patients .
-
Announced!
Time of Update: 2021-12-26
It is necessary to plan ahead, make overall arrangements, focus on key and difficult issues and take the lead in breaking through, focus on achieving full coverage of DRG/DIP paid hospitals and disease types, focus on implementing relevant national standards and working mechanisms, and focus on improving professional capabilities and informatization levels.
-
Since December, a large number of pharmaceutical companies are intensively listing!
Time of Update: 2021-12-26
On December 15, BeiGene was listed on the Science and Technology Innovation Board and became the world's first biopharmaceutical company listed on the US, Hong Kong and A shares .
On December 10, Dizhe Pharmaceutical was listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange .
-
Haixiang Pharmaceutical changed the chairman, supervisors and by-election of directors
Time of Update: 2021-12-26
Sun Yang applied to resign from the positions of the chairman of the company's sixth board of directors and a member of the special committees under the board of directors.
Wang Qihua applied for his resignation as a supervisor of the company's sixth board of supervisors due to personal reasons.
-
Over 800 medicines were sold and used during the year!
Time of Update: 2021-12-26
On December 9, the State Food and Drug Administration issued an announcement on the cancellation of 210 drug registration certificates including chloramphenicol tablets (No.
. On May 19, the State Food and Drug Administration issued an announcement on the cancellation of registration certificates of 283 drugs including megestrol acetate dispersible tablets (No.
-
New anti-inflammatory drugs!
Time of Update: 2021-12-26
(Skyline Therapeutics, hereinafter referred to as "Nine-Day Bio", the original Geneception), and BioMarin announced that they have reached a multi-year global strategic cooperation to jointly research and develop gland-based Novel gene therapy of virus (AAV) is used to treat inherited cardiovascular diseases .
-
The number of innovative Chinese medicines approved in 2021 hits a record high, reaching 11
Time of Update: 2021-12-26
For example, on August 27, the Drug Evaluation Center of the State Food and Drug Administration issued the "Technical Guidelines for the Pharmaceutical Research of Chinese Medicine Compound Preparations Managed in the Catalogue of Ancient Classical Prescriptions (for Trial Implementation)", clarifying that the Chinese medicine compound preparations managed in accordance with the catalogue of ancient classic prescriptions belong to Chinese medicine registration classification 3.
-
In the $21.8 billion drug market, pharmaceutical companies are accelerating their deployment!
Time of Update: 2021-12-26
According to the letter, CT041 has also become the world’s first CAR T cell candidate product that has been approved by the US FDA, the National Food and Drug Administration and Health Canada’s IND and is undergoing clinical trials to target CLDN 18.
-
Flowers are easy to see and hard to find: how many of the top 10 predictions at the beginning of the year have been made?
Time of Update: 2021-12-26
Lag-3 replaced Tigit as the preferred combination partner of PD-1, and HPK became a popular target for small molecules• Lag-3 has become one of the few new IO drugs that have succeeded in Phase III clinical trials and has surpassed TIGIT in momentum, but TIGIT is still a popular target .
-
Paragraph 4!
Time of Update: 2021-12-26
Article source: Pharmaceutical GuanlanOn December 16, according to the latest announcement on the official website of China's National Medical Products Administration (NMPA), the new drug application for omadacycline tosylate (omadacycline, trade name: Nuzyra) declared by Zai Lab has been approved .
-
It's coming!
Time of Update: 2021-12-26
The summary report of the circle of friends of the medicine machine in 2021 is released (picture source: Pharmaceutical Network) In terms of the performance of this year's plan, the three representative domestic medicine equipment companies, Chutian Technology, Dongfulong, and Canaan Technology are used as examples.
